Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus bendamustine + rituximab versus placebo plus bendamustine + rituximab in newly diagnosed mantle cell lymphoma (Phase 3)
2012-004056-11Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in mantle cell lymphoma (MCL) comparing Ibrutinib + bendamustine + rituximab with Placebo + bendamustine + rituximab (2 arms). Primary endpoint: Progression-free survival. Started Jan 2013; status: completed.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2012-004056-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004056-11.